MedWatch

Danish CROs benefit from life science growth spurt

Though competition on the contract research market is getting fiercer the demand for clinics is also increasing. Three of Denmark's biggest contract research organizations anticipate growth during the next couple of years.

Foto: pr

As the number of biotech companies increase and more drug groups license out their clinical research, things are looking up for Danish contract research organizations (CROs) - despite a massive pressure of competition from foreign rivals.

This is according to the leaders of three of Denmark's biggest CROs: Klifo, Larix and Bioclinica Danmark (former CCBR-Synarc).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier